January 11, 2017 / 11:59 AM / 6 months ago

BRIEF-Eli Lilly and Merck expand immuno-oncology collaboration

1 Min Read

Jan 11 (Reuters) - Eli Lilly And Co

* Lilly and Merck expand immuno-oncology collaboration

* Eli Lilly and co - financial details of collaboration were not disclosed.

* Lilly is sponsor of Phase 1 study and enrollment is expected to begin mid-2017.

* Eli Lilly - expansion of collaboration with Merck to add new study of lartruvo with keytruda in patients with previously treated soft tissue sarcoma Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below